Pfago mutant protein having target nucleic acid cleavage activity at medium temperatures and use thereof
Through structural mutation of PfAgo protein, a PfAgo_K617G/L618G mutant with activity at 37°C was developed, which solved the problem of insufficient activity of PfAgo protein at low temperatures, expanded its application range, and maintained heat resistance at high temperatures , suitable for a variety of biotechnology applications.
Patent Information
- Application Number
- PCT/CN2023/104637
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2023-06-30
- Publication Date
- 2024-11-21
AI Technical Summary
The PfAgo protein has almost no activity at 37°C, which limits its possibility of application for intracellular RNA and genome editing, and high-temperature active enzymes are inconvenient to preserve and transport at low temperatures, limiting its application scope.
By performing structural mutations on the PfAgo protein, especially the amino acid mutations at positions 617 and 618, PfAgo mutant proteins with medium-temperature target nucleic acid cleavage activity were developed, such as PfAgo_K617G/L618G, which amplified its cleavage at 37°C Activity and scope of application.
PfAgo_K617G/L618G mutant protein has significant target DNA and RNA cleavage activity at 37°C, retaining heat resistance at high temperatures, expanding the application range, and providing more flexible usage conditions, suitable for nucleic acid detection and molecular cloning. and genome editing and other fields.
Smart Images

Figure CN2023104637_21112024_PF_FP_ABST
Abstract
Description
PfAgo mutant protein with medium-temperature target nucleic acid cleavage activity and its application Technical Field
[0001] The present invention belongs to the technical field of programmable nucleases, and in particular relates to a PfAgo mutant protein having medium-temperature target nucleic acid cleavage activity and applications thereof. Background Art
[0002] Argonaute (Ago) proteins are a novel class of programmable nucleases widely distributed in eukaryotes, eubacteria, and archaea. Most eukaryotic Ago (eAgo) proteins have been found to use a 5'-phosphorylated guide RNA (5'P-gRNA) to recognize target RNA, playing a crucial role in the RNA interference (RNAi) pathway in eukaryotes. Most prokaryotic Ago (pAgo) proteins use a 5'-phosphorylated guide DNA (5'P-gDNA) to recognize target DNA. Prokaryotes lack an RNAi pathway. Although recent studies have shown that pAgo proteins can defend against invasive genetic elements and participate in various intracellular activities, the physiological functions of pAgo proteins remain largely unclear. CRISPR-associated proteins, as programmable nucleases, have been reported to be applicable in various fields. Similar to CRISPR-associated proteins, Ago proteins, as a novel class of programmable nucleases, have been reported to be applicable in molecular cloning, molecular diagnostics, intracellular RNA and genome editing, and in vivo imaging. Compared with the CRISPR-Cas system, which requires specific motifs on the target and can only use RNA as a guide chain, the pAgo protein exhibits precise endonuclease activity on any target sequence and can use both RNA and DNA as guide nucleic acids. Therefore, it has great potential in applications such as intracellular RNA and genome editing.
[0003] PfAgo is a pAgo protein derived from the extremely thermophilic bacterium Pyrococcus furiosus. It can cleave target DNA under the guidance of 5'P-gDNA. Its activity is highest in the temperature range of 87-99.99°C, while it is unable to cleave target DNA for a short period of time at 37°C. PfAgo's high 5'P-gDNA-mediated DNA cleavage activity at high temperatures has led to its application in molecular cloning and molecular diagnostics. However, its near-inactivity at 37°C limits its potential for intracellular RNA and genome editing. Furthermore, enzymes that are thermostable and catalytically active at low temperatures are not only easier to store but also have a wider range of applications.
[0004] Adaptation of organisms to their environmental niches is a hallmark of evolution. A common example is thermoadaptation, in which two progeny evolve at different extreme temperatures. Physiological differences between these organisms underlie variations in the enzymes catalyzing essential reactions. Homologs from each organism undergo adaptive mutations, maintaining similar catalytic rates at their respective physiological temperatures. However, the sequence changes that drive these adaptive differences often occur at surface-exposed sites distal to the substrate binding site, leaving the enzyme's active site structurally undisturbed. How these changes propagate allosterically to the active site to modulate activity remains unclear. In 2018, Harry G. Saavedra et al. proposed that dynamic allostery can promote enzyme cold adaptation by selectively mutating allosteric sites to increase the probability of local unfolding while preserving the ground-state structure. In 2019, Satoshi Akanuma et al. demonstrated an efficient method to explore amino acid substitutions to enhance the low-temperature catalytic activity of thermophilic enzymes, based on sequence alignments of a panel of thermophilic and mesophilic enzymes.
[0005] Summary of the Invention
[0006] In view of this, the present invention aims to conduct structure-based mutant screening of PfAgo protein to discover PfAgo mutant proteins with better activity under medium temperature conditions. This can not only pave the way for intracellular RNA targeting and gene editing and other applications, expand the scope of use of pAgo protein, but also provide a strategy for modifying high-temperature Ago protein.
[0007] The technical solutions of the present invention are as follows:
[0008] One of the purposes of the present invention is to provide a PfAgo mutant protein having medium-temperature target nucleic acid cleavage activity. Compared with the wild-type PfAgo protein, these mutant proteins are structurally distant from the active site and the binding substrate. outside The amino acids within the range of α and β have mutated, which changes the catalytic activity temperature. The active site of the present invention specifically refers to the DEDH catalytic quadruplex of the wild-type PfAgo protein.
[0009] Specifically, the mutation site of the PfAgo mutant protein provided by the present invention is position 617 and / or position 618 of the sequence shown in SEQ ID NO.1 (amino acid sequence of wild-type PfAgo protein); in the sequence shown in SEQ ID NO.1, the amino acid at position 617 is lysine (Lys, K), and the amino acid at position 617 is leucine (Leu, L).
[0010] In the PfAgo mutant protein provided by the present invention, the lysine at position 617 is mutated to any amino acid other than lysine, and the leucine at position 618 is mutated to any amino acid other than leucine.
[0011] Compared with the wild-type PfAgo protein, the PfAgo mutant protein provided by the present invention has target nucleic acid cleavage activity at 30-95°C, which expands the scope of application of the PfAgo protein and makes it have the potential to be used in intracellular RNA and genome editing.
[0012] Preferably, in the PfAgo mutant protein provided by the present invention, the lysine at position 617 is mutated to glutamic acid (Glu, E) or glycine (Gly, G), denoted as K617E / G; the leucine at position 618 is mutated to tyrosine (Tyr, Y), phenylalanine (Phe, F), tryptophan (Trp, W) or glycine, denoted as L618Y / F / W / G.
[0013] The data of the embodiment of the present invention show that:
[0014] (a1) When lysine 617 is mutated to glutamic acid or glycine, the resulting two mutant proteins are able to cleave the target DNA under the guidance of the guide DNA. Among them, the mutant protein obtained after lysine 617 is mutated to glycine has better activity at 37°C;
[0015] (a2) When leucine at position 618 is mutated to tyrosine, phenylalanine, tryptophan, and glycine, respectively, the resulting four mutants are able to cleave target DNA under the guidance of guide DNA. Among them, when leucine at position 618 is mutated to tyrosine or glycine, the resulting mutant protein has better activity at 37°C and can also cleave target RNA under the guidance of guide DNA. The mutant protein obtained when leucine at position 618 is mutated to glycine can also cleave target RNA under the guidance of 5'P-gRNA.
[0016] (a3) When positions 617 and 618 were mutated simultaneously, specifically to glycine and tyrosine, respectively (i.e., K617E and L618Y), or to glycine (i.e., K617G and L618G), the resulting two mutant proteins exhibited enhanced activity at 37°C and were capable of cleaving target DNA and RNA under the guidance of guide DNA. Among them, the mutant protein obtained by simultaneously mutating positions 617 and 618 to glycine (denoted as PfAgo_K617G / L618G) exhibited optimal activity at 37°C and was also capable of cleaving target RNA under the guidance of 5'P-gRNA.
[0017] A second object of the present invention is to provide some biological materials related to the above-mentioned PfAgo mutant protein, including:
[0018] (b1) a nucleic acid molecule encoding a PfAgo mutant protein;
[0019] (b2) an expression cassette or vector comprising the nucleic acid molecule described in (b1);
[0020] (b3) A transformant comprising the vector described in (b2).
[0021] For the nucleic acid molecule described in (b1), one embodiment of the present invention provides a nucleotide sequence as shown in SEQ ID NO.3, and the PfAgo mutant protein encoded by the sequence (i.e., PfAgo_K617G / L618G) is a protein in which lysine at position 617 and leucine at position 618 are simultaneously mutated to glycine, and the amino acid sequence of the mutant protein is shown in SEQ ID NO.2.
[0022] The vector described in (b2) may be a pET plasmid. For example, in one embodiment of the present invention, a nucleic acid fragment encoding a PfAgo mutant protein is connected to pET-28a to obtain a recombinant vector.
[0023] The transformant described in (b3) is obtained by transforming the recombinant vector into a host cell. The host cell can be a conventional host cell in the art, but it must be able to satisfy the stable self-replication of the recombinant vector and the nucleic acid molecule encoding the PfAgo mutant protein carried by it can be effectively expressed.
[0024] The PfAgo mutant protein can be prepared using the above-mentioned biological materials.
[0025] A third object of the present invention is to provide a nucleic acid cleavage system, which comprises:
[0026] (c1) single-stranded guide nucleic acid;
[0027] (c2) The PfAgo mutant protein provided by the present invention.
[0028] In the above nucleic acid cleavage system, the single-stranded guide nucleic acid is 5'P-gRNA, 5'P-gDNA or 5'-terminal hydroxylated guide DNA (5'OH-gDNA), and the length of the single-stranded guide nucleic acid is 12 to 30 nucleotides.
[0029] More preferably, the single-stranded guide nucleic acid is 15 to 19 nucleotides in length, with 18 nucleotides being the most preferred length.
[0030] A fourth object of the present invention is to provide an application of the above-mentioned nucleic acid cleavage system in specifically cleaving target RNA or target DNA. Specifically, a nucleic acid cleavage system is constructed, and target RNA or target DNA is added to the system. If the target RNA or target DNA is complementary to the single-stranded guide nucleic acid sequence, the PfAgo mutant protein specifically cleaves the target RNA or target DNA under the guidance of the single-stranded guide nucleic acid.
[0031] In the above applications, the target RNA has no higher order structure, or has a higher order structure, or is double-stranded RNA, or is in vitro transcribed RNA, or is viral genomic RNA, or is mRNA, or is other RNA in the cell. The target DNA is single-stranded DNA or double-stranded DNA.
[0032] In the above applications, complementary pairing specifically refers to the following two situations:
[0033] The target RNA or target DNA has a nucleotide sequence that is completely complementary to the single-stranded guide nucleic acid sequence;
[0034] The target RNA or target DNA has a nucleotide sequence that has single or multiple base mismatches with the single-stranded guide nucleic acid sequence, wherein the number of mismatches may be 1, 2, 3, 4 or 5, and the mismatches are usually isolated or may be continuous.
[0035] In the above application, the nucleic acid cleavage system contains a 2+ , Mg 2+ and Co 2+ At least one divalent metal cation.
[0036] Preferably, the divalent metal cation is Mn 2+ and Mg 2+ , the best of which is Mn 2+ .
[0037] Preferably, in the nucleic acid cleavage system, the final concentration of the divalent metal cation is 1 to 10 mM; the data in the embodiment show that when the single-stranded guide nucleic acid is 5'P-gDNA and the target is DNA, Mg 2+ The concentration is 3~10mM, Mn 2+ The concentration is 2 to 10 mM; when the single-stranded guide nucleic acid is 5'P-gDNA and the target is RNA, Mg 2+ The concentration is 2~10mM, Mn 2+ The concentration is 1 to 5 mM; when the single-stranded guide nucleic acid is 5'P-gRNA and the target is RNA, Mn 2+ The concentration is 3-10mM.
[0038] A fifth object of the present invention is to provide a detection kit, which contains the PfAgo mutant protein provided by the present invention; and may also contain a single-stranded guide nucleic acid with a specific sequence according to the purpose of detection.
[0039] The sixth object of the present invention is to provide an in vitro gene editing method, specifically using the PfAgo mutant protein provided by the present invention.
[0040] Compared with the prior art, the present invention has the following beneficial effects:
[0041] (1) By structurally separating the wild-type PfAgo protein from the active site and the binding substrate outside By mutating the amino acids within, we successfully screened out PfAgo mutant proteins with good activity under medium and low temperature conditions, providing a strategy for the modification of high-temperature Ago proteins.
[0042] (2) The PfAgo mutant protein provided by the present invention improves its cleavage activity at moderate temperatures while retaining its heat resistance, which is beneficial for the storage and transportation of the enzyme.
[0043] (3) Compared with the wild-type PfAgo, which can only cut target DNA using guide DNA at high temperature, the optimal mutant protein PfAgo_K617G / L618G provided by the present invention can cut target DNA and RNA using guide DNA at 37°C, and cut RNA target using 5'P-gRNA, which expands its usable temperature range, the type of guide nucleic acid, and the type of cut target.
[0044] (4) PfAgo_K617G / L618G has the activity of specifically cleaving target RNA and target DNA. The present invention also provides a nucleic acid expression vector encoding the PfAgo_K617G / L618G protein, as well as compositions, kits, and methods for cleaving and editing target nucleic acids in a sequence-specific manner, laying the foundation for the application of PfAgo_K617G / L618G in many fields of biotechnology, such as nucleic acid detection, molecular cloning, RNA, and genome editing.
[0045] (5) PfAgo_K617G / L618G can use guide DNA to cut target DNA at 37°C, laying the foundation for its in vivo genome editing; PfAgo_K617G / L618G can use guide DNA to cut target RNA at 37°C, laying the foundation for its in vivo RNA targeting; PfAgo_K617G / L618G can use 5'P-gRNA to cut target RNA at 37°C, laying the foundation for its in vivo RNA targeting by co-expression of protein and guide nucleic acid.
[0046] (6) PfAgo_K617G / L618G strictly relies on the complementary pairing of the guide and the target to exert its cleavage activity. There is no non-specific "incidental cleavage" activity of CRISPR-related proteins, and the specificity is better. The types of guide nucleic acids used by PfAgo_K617G / L618G are diverse and can be either DNA or RNA. They are generally shorter in length. The synthesis cost of DNA is relatively lower than that of RNA, and DNA is more stable than RNA and is not easily degraded. The pAgo complex formed by PfAgo_K617G / L618G and the guide nucleic acid does not rely on special motifs near the target site to recognize and bind to the target. The guide nucleic acid is easy to design and there is no need to consider site restrictions. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] FIG1 is a diagram showing the SDS-PAGE analysis results of the PfAgo protein and some of its mutant proteins in Example 1;
[0048] FIG2 is a urea / polyacrylamide gel assay result of the products obtained by cleaving single-stranded target DNA or target RNA by PfAgo_K617E, PfAgo_L618Y, and PfAgo_K617E / L618Y in Example 2;
[0049] FIG3 is a urea / polyacrylamide gel assay result of the products obtained by cleaving single-stranded target DNA or target RNA by PfAgo_L618F and PfAgo_L618W in Example 2;
[0050] FIG4 is a urea / polyacrylamide gel assay result of the products obtained by cleaving single-stranded target DNA or target RNA by PfAgo_K617G, PfAgo_L618G, and PfAgo_K617G / L618G in Example 2;
[0051] Figure 5 is a urea / polyacrylamide gel assay result of the products obtained by cleaving the target DNA by PfAgo and its mutants PfAgo_K617E, PfAgo_L618Y and PfAgo_K617E / L618Y under the guidance of 5'P-gDNA in Example 3;
[0052] FIG6 is a urea / polyacrylamide gel assay result of the products obtained by cleaving single-stranded target DNA or target RNA by PfAgo_K617G / L618G under the guidance of guide nucleic acids of different lengths in Example 4;
[0053] FIG7 is a urea / polyacrylamide gel assay result of the products obtained by cleaving single-stranded target DNA or target RNA by PfAgo_K617G / L618G under different metal cation conditions in Example 5;
[0054] Figure 8 shows the results of PfAgo_K617G / L618G in Example 5 at different Mn 2+ or Mg 2+ Urea / polyacrylamide gel assay results of products obtained by cleaving single-stranded target DNA or target RNA under ionic concentration conditions;
[0055] FIG9 is a urea / polyacrylamide gel assay result of the products obtained by cleaving single-stranded target DNA or target RNA by PfAgo_K617G / L618G under the guidance of guide nucleic acids with different 5' terminal nucleotides in Example 6;
[0056] FIG10 is a graph showing the target cleavage kinetic analysis results of PfAgo_K617G / L618G in Example 7;
[0057] Figure 11 is a urea / polyacrylamide gel assay result of the products obtained by cleaving single-stranded target DNA or target RNA by PfAgo_K617G / L618G under different single-base mismatch conditions in Example 8;
[0058] Figure 12 is a graph showing the detection results of the products obtained by cleaving plasmid DNA with PfAgo_K617G / L618G in Example 9;
[0059] FIG13 is a graph showing the detection results of products obtained by cleaving target DNA with PfAgo_K617G / L618G at different nucleic acid guide incubation temperatures in Example 10;
[0060] FIG14 is a graph showing the urea / polyacrylamide gel assay results of products obtained by cleaving target DNA or RNA with PfAgo_K617G / L618G at different reaction temperatures in Example 11;
[0061] FIG15 is a graph comparing the cleavage rates of the wild-type PfAgo protein and PfAgo_K617G / L618G on the target DNA at 95° C. in Example 12. DETAILED DESCRIPTION
[0062] The technical solutions of the present invention will be described clearly and completely below in conjunction with the embodiments and the accompanying drawings. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments.
[0063] Unless otherwise specified, all examples were prepared under conventional experimental conditions or the conditions recommended by the manufacturer's instructions. All reagents and materials used were commercially available unless otherwise specified.
[0064] Example 1 Screening and preparation of PfAgo mutants
[0065] (1) Screening of PfAgo structure-based mutation sites.
[0066] The structure of PfAgo (PDB ID: 1U04) and the structure of the CbAgo ternary complex (PDB ID: 6QZK) were downloaded from the PDB official website. First, the structures of the PfAgo and CbAgo ternary complex were loaded into the PyMOL software. Then, the structures of PfAgo and CbAgo were compared and the mutation sites were screened based on the following three principles: first, the side chain of the mutation site should be highly exposed on the surface and have no intramolecular contact; second, the mutation side chain should be far away from the binding substrate and the active site (i.e. ); the third is to select the distance between the binding substrate and the active site Amino acids within a certain distance.
[0067] The PfAgo gene fragment shown in SEQ ID NO. 1 was amplified from the recombinant plasmid pET23a-PfAgo and ligated to pET28a using conventional methods to obtain the pET28a-PfAgo plasmid.
[0068] PfAgo mutants were constructed based on the screened mutation sites, including: PfAgo_K617E, which mutated lysine at position 617 to glutamate, PfAgo_K617G, which mutated lysine at position 617 to glycine, PfAgo_L618Y, which mutated leucine at position 618 to tyrosine, PfAgo_L618F, which mutated leucine at position 618 to phenylalanine, PfAgo_L618W, which mutated leucine at position 618 to tryptophan, and PfAgo_L618G, which mutated leucine at position 618 to glycine. Further combined mutations were performed on PfAgo, including simultaneously mutating lysine at position 617 and leucine at position 618 to glutamate and tyrosine, respectively, to obtain PfAgo_K617E / L618Y, and simultaneously mutating lysine at position 617 and leucine at position 618 to glycine to obtain PfAgo_K617G / L618G. The amino acid sequence and nucleotide sequence of these mutants, PfAgo_K617G / L618G, are shown in SEQ ID NO. 2 and SEQ ID NO. 3.
[0069] Primers were designed for different sites, PCR was performed using the pET28a-PfAgo plasmid as a template, and the mutant plasmids were obtained by T5 recombination cloning.
[0070] (2) Expression and purification of PfAgo and its mutants.
[0071] PfAgo and its mutant plasmids were transformed into Escherichia coli BL21 (DE3) respectively, and single colonies were picked and placed in 5 mL of LK liquid medium, cultured overnight at 37 ° C in a shaking incubator, and then transferred to a large bottle of TB medium containing 50 mg / mL kanamycin at a ratio of 5:1 for culture. 600 When the value was 0.6-0.8, IPTG was added to a final concentration of 0.5 mM and protein expression was induced in a shaking incubator at 18°C for 16-20 h.
[0072] Use a high-speed centrifuge to centrifuge at 6000rpm for 10 minutes to collect the bacteria, remove the supernatant, resuspend the collected bacteria in Buffer A (20mM Tris-HCl, pH 7.5, 400mM NaCl, 5% glycerol, 1mM DTT), add the protease inhibitor PMSF with a final concentration of 1mM, then use a high-pressure homogenizer to lyse the cells, and then use a refrigerated high-speed centrifuge to centrifuge at 18000rpm for 50 minutes. Filter the supernatant with a 0.45μm filter membrane. Take an appropriate amount of Ni-NTA resin and add it to the gravity purification column. Use 3 times the volume of Ni beads and Buffer A containing 10mM imidazole to activate the Ni beads three times. Add the filtered supernatant to the gravity purification column containing Ni-NTA resin and combine it with a silent mixer in a 4°C chromatography cabinet for 50 minutes. First, wash with Buffer A containing 20mM and 50mM imidazole to remove impurities, and then elute with Buffer A containing 75mM, 100mM, 200mM, 300mM, 400mM, and 500mM imidazole to obtain the target protein. The volume of each wash is 3 to 5 times the volume of the Ni beads.
[0073] Transfer 40 μL of the lysis supernatant, flow-through, and eluate from the different imidazole gradients to a 1.5 mL centrifuge tube. Add 10 μL of 5× protein loading buffer and incubate at 100°C for 10 minutes to denature the protein. Prepare a 10% SDS-PAGE gel and analyze the protein Ni-bead affinity purification results using SDS-PAGE. Select the eluted target protein of higher purity and concentrate it by ultrafiltration using Amicon 50K ultrafiltration tubes. Aliquot the concentrated protein, quickly freeze it with liquid nitrogen, and store it at -80°C.
[0074] The SDS-PAGE identification analysis results of PfAgo and some of its mutants are shown in Figure 1. As shown in Figure 1, 20-50 mM imidazole can remove most of the impurities, and the purity of the target protein eluted at 75-400 mM is comparable.
[0075] Finally, the target protein eluted with 75mM to 400mM imidazole was selected for ultrafiltration and concentration.
[0076] After Ni-bead affinity purification, the A260 / A280 ratio of PfAgo and its mutant proteins was measured to determine the amount of endogenous nucleic acid bound during expression in E. coli. Ni-bead affinity-purified PfAgo and its mutant proteins exhibited A260 / A280 ratios around 0.65, indicating they were suitable for subsequent experiments without further purification.
[0077] Example 2 Determination of cleavage activity of various PfAgo mutants at moderate temperature
[0078] The activity of the selected PfAgo mutants was verified at 37°C. Four types of single-stranded guide nucleic acids (ssGNs) were used to cleave target DNA and RNA: 5'OH-gDNA, 5'P-gDNA, 5'-hydroxylated guide RNA (5'OH-gRNA), and 5'P-gRNA. The sequences of the guide nucleic acids and targets used in this example are shown in Table 1.
[0079] Table 1
[0080] To an enzyme-free PCR tube, add the guide nucleic acid to a final concentration of 1 μM, 1 μM PfAgo mutant protein, 1× digestion buffer (10 mM HEPES pH 7.5, 100 mM NaCl, 5% glycerol, 5 mM MnCl), and 0.8 U / 10 μL RNase inhibitor, and incubate at 37°C for 10 minutes. Then, add 200 nM 5'-end FAM-labeled target DNA or RNA, and incubate at 37°C for 30 minutes for target cleavage. The reaction is terminated by mixing the sample with 2× RNA loading dye (95% formamide, 18 mM EDTA, 0.025% SDS, and 0.025% bromophenol blue) and heating at 95°C for 5 minutes. Cleavage products are detected by electrophoresis on a 20% denaturing polyacrylamide gel and visualized using a gel imaging system.
[0081] The results of cleavage of single-stranded target DNA and target RNA by PfAgo_K617E, PfAgo_L618Y and PfAgo_K617E / L618Y are shown in Figure 2. As shown in Figure 2, both PfAgo_K617E and PfAgo_L618Y can cleave complementary target DNA under the guidance of 5'OH-gDNA and 5'P-gDNA, but the cleavage activity of PfAgo_K617E is weaker than that of PfAgo_L618Y; moreover, P fAgo_L618Y can also cut complementary target RNA under the guidance of 5'OH-gDNA and 5'P-gDNA; PfAgo_K617E / L618Y obtained by combined mutation of these two sites further improved its activity at room temperature. PfAgo_K617E / L618Y can cut target DNA and RNA under the guidance of 5'OH-gDNA and 5'P-gDNA at 37°C, and has a preference for target DNA.
[0082] The cleavage results of PfAgo_L618F and PfAgo_L618W on single-stranded target DNA and target RNA are shown in Figure 3. As can be seen from Figure 3, both PfAgo_L618F and PfAgo_L618W can cleave complementary target DNA under the guidance of 5'OH-gDNA and 5'P-gDNA at 37°C, but cannot cleave target RNA.
[0083] The results of PfAgo_K617G, PfAgo_L618G and PfAgo_K617G / L618G cleaving single-stranded target DNA and target RNA are shown in Figure 4. As shown in Figure 4, PfAgo_K617G can use 5'OH-gDNA and 5'P-gDNA to cleave complementary target DNA, and its activity is stronger than that of PfAgo_K617E; PfAgo_L618G can use 5'OH-gDNA and 5'P-gDNA to cleave complementary target DNA and RNA, and its activity is stronger than that of PfAgo_L618G. 618Y is strong, and PfAgo_L618Y can also use 5'P-gRNA to cut complementary target RNA, even though the activity is weak; PfAgo_K617G / L618G obtained by combined mutation of these two sites further improves its activity at room temperature. PfAgo_K617G / L618G can use 5'OH-gDNA and 5'P-gDNA to cut complementary target DNA at 37°C, and use 5'OH-gDNA, 5'P-gDNA, and 5'P-gRNA to cut complementary target RNA.
[0084] Example 3 Determination of cleavage activity of PfAgo mutants at high temperature
[0085] Referring to Example 2, this example used mutants PfAgo_K617E, PfAgo_L618Y, and PfAgo_K617E / L618Y to perform 5' P-gDNA-guided target DNA cleavage experiments at 37° C. and 95° C., respectively (with PfAgo as a control).
[0086] The cleavage results of single-stranded target DNA by PfAgo_K617E, PfAgo_L618Y and PfAgo_K617E / L618Y are shown in FIG5 . As can be seen from FIG5 , PfAgo_K617E, PfAgo_L618Y and PfAgo_K617E / L618Y are not only able to cleave at 37°C, but also maintain high activity at 95°C.
[0087] Example 4 Effect of Guide Nucleic Acid Length on PfAgo_K617G / L618G Cleavage Activity
[0088] This example uses the mutant PfAgo_K617G / L618G as an example to explore the optimal length of the guide nucleic acid.
[0089] According to the guide nucleic acid sequence and target sequence in Example 2, gDNA and gRNA with a length of 12 to 30 nt were synthesized, wherein the sequence of the 30 nt gDNA is shown in Table 2, and the sequence of the 12 to 25 nt gDNA is consistent with the first 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, and 25 base sequences of the sequence; the sequence of the 30 nt gRNA is shown in Table 2, and the sequence of the 12 to 25 nt gRNA is consistent with the first 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, and 25 base sequences of the sequence. The 5' end sequences of these guide nucleic acids are the same, so the cleavage site and the size of the cleavage product should be the same. The synthesized guide nucleic acids of different lengths were 5' end phosphorylated, and the cleavage experiments of target DNA and RNA were carried out with 5' P-gDNA of different lengths, and the cleavage experiments of target RNA were carried out with 5' P-gRNA of different lengths. The experimental process is referred to Example 2.
[0090] Table 2
[0091] Detection was performed using 20% urea / polyacrylamide gel electrophoresis, and the results are shown in Figure 6. The results showed that PfAgo_K617G / L618G can cleave target DNA using 5'P-gDNA of 13-25 nt in size, and exhibits the highest enzymatic activity under the guidance of an 18-nt guide nucleic acid. PfAgo_K617G / L618G can cleave target RNA under the guidance of 5'P-gDNA of 12-30 nt in size, and exhibits higher enzymatic activity under the guidance of a 15-18 nt guide nucleic acid. PfAgo_K617G / L618G can cleave target RNA under the guidance of 5'P-gRNA of 13-21 nt in size, and exhibits higher enzymatic activity under the guidance of a 14-19 nt guide nucleic acid.
[0092] Example 5 Effects of different divalent metal ions on the cleavage activity of PfAgo_K617G / L618G
[0093] In this case, the mutant PfAgo_K617G / L618G was used as an example to explore the effect of the type of divalent metal ions in the cleavage system on the cleavage activity of the mutant.
[0094] The experimental process was referred to Example 2, but different from Example 2, MnCl2 in the enzyme cleavage reaction buffer was replaced by FeCl2, CoCl2, NiCl2, CuCl2, ZnCl2, CaCl2, MgCl2 and EDTA of the same concentration to carry out 5'P-gDNA-guided tDNA, tRNA and 5'P-gRNA-guided tRNA cleavage experiments.
[0095] Detection was performed using 20% urea / polyacrylamide gel electrophoresis, and the results are shown in Figure 7. The results showed that for the cleavage of target DNA guided by 5'P-gDNA, PfAgo_K617G / L618G can use Co 2+ Mg 2+ and Mn 2+ As a divalent metal ion, and in the presence of Mn 2+ The activity is best in the enzyme digestion buffer; for the cleavage of the target RNA guided by 5'P-gDNA, PfAgo_K617G / L618G can also use Co 2+ Mg 2+ and Mn 2+ As a divalent metal ion, and in the presence of Mn 2+ The activity is best in the enzyme digestion buffer; for the cleavage of target RNA guided by 5'P-gRNA, PfAgo_K617G / L618G can only be used with Co 2+ and Mn 2+ As a divalent metal ion, and in the presence of Mn2+ The activity was best in the enzyme digestion buffer. Therefore, the optimal divalent metal ion for PfAgo_K617G / L618G is Mn 2+ .
[0096] This example further investigates the different concentrations of Mn 2+ and Mg 2+ Effects of different concentrations of Mn on the cleavage activity of PfAgo_K617G / L618G. 2+ and Mg 2+ The cleavage activity of PfAgo_K617G / L618G was tested under (1, 2, 3, 4, 5, 10 mM) conditions.
[0097] Detection was performed using 20% urea / polyacrylamide gel electrophoresis, and the results are shown in Figure 8. The results showed that when 5'P-gDNA was used to target the complementary single-stranded DNA, Mg 2+ Titration experiments showed that PfAgo_K617G / L618G had catalytic activity at ion concentrations of 1 to 10 mM, and the activity was strongest at 10 mM. 2+ Titration experiments showed that PfAgo_K617G / L618G had catalytic activity at ion concentrations of 1 to 10 mM, and the activity was stronger and comparable at ion concentrations of 2 to 10 mM. When 5'P-gDNA was used to target complementary RNA, Mg 2+ Titration experiments showed that PfAgo_K617G / L618G had catalytic activity at ion concentrations of 1 to 10 mM, and had stronger activity at ion concentrations of 2 to 10 mM, but the activity was generally weaker; Mn 2+ Titration experiments showed that PfAgo_K617G / L618G had catalytic activity at 1-10 mM ion concentrations and the cleavage activity was comparable. When 5'P-gRNA was used to target complementary RNA, Mg 2+ Titration experiments showed that Mg 2+ Even if the ion concentration is increased to 10mM, PfAgo_K617G / L618G cannot perform target cleavage; Mn 2+ Titration experiments showed that PfAgo_K617G / L618G had catalytic activity at ion concentrations of 1 to 10 mM, and the activity was stronger and comparable at ion concentrations of 3 to 10 mM.
[0098] Example 6 Effect of the 5' terminal nucleotide of the guide nucleic acid on the enzymatic activity of PfAgo_K617G / L618G
[0099] In this study, the mutant PfAgo_K617G / L618G was used as an example to investigate the effect of the 5'-terminal nucleotide of the guide nucleic acid on the enzyme cleavage activity of the mutant.
[0100] Referring to the guide nucleic acid sequences in Example 2, a series of 5'-terminally phosphorylated DNA and RNA guide nucleic acids were designed and synthesized. These guide nucleic acids had different 5'-terminal nucleotides (A, T, G, C) but otherwise shared the same sequence. Correspondingly, a series of target DNA and RNA complementary to each guide nucleic acid were also synthesized. The sequences of the corresponding targets are shown in Table 3.
[0101] Table 3
[0102] The activity of cutting single-stranded DNA and RNA was tested under the guidance of 5'P-gDNA with different 5' terminal nucleotides, and the activity of cutting RNA was tested under the guidance of 5'P-gRNA with different 5' terminal nucleotides (the test process was the same as in Example 2), and 20% urea / polyacrylamide gel electrophoresis was used for detection, and the test results are shown in Figure 9.
[0103] The results showed that when PfAgo_K617G / L618G cleaved complementary single-stranded target DNA under the guidance of 5'P-gDNA, the cleavage activity mediated by the guide nucleic acid containing 5'-A was slightly higher than that mediated by the guide nucleic acids containing 5'-T, 5'-G, and 5'-C, and the cleavage activities mediated by the guide nucleic acids containing 5'-T, 5'-G, and 5'-C were comparable; when PfAgo_K617G / L618G cleaved complementary target RNA under the guidance of 5'P-gDNA and 5'P-gRNA, no obvious preference for the 5'-terminal nucleotide was observed, and the cleavage activities mediated by the guide nucleic acids containing 5'-A, 5'-T / U, 5'-G, and 5'-C were comparable.
[0104] Example 7 Target Cleavage Kinetic Analysis of PfAgo_K617G / L618G
[0105] In this study, the target cleavage kinetics of PfAgo_K617G / L618G were investigated. Experimental conditions and procedures were similar to those in Example 2. 5'P-gDNA-guided tDNA, tRNA, and 5'P-gRNA-guided tRNA cleavage experiments were performed at 37°C for various reaction times (0, 5, 10, 15, 30, 45, and 60 minutes). Cleavage products were detected by 20% denaturing polyacrylamide gel electrophoresis and visualized using a gel imaging system.
[0106] The above experiment was repeated three times. Denaturing PAGE gel images were scanned in grayscale using ImageJ software. PfAgo cleavage ratios were calculated using Microsoft Excel software. Prism 8 (GraphPad) software was used to plot the data and perform statistical analysis. Data are presented as the mean ± SD of three independent experiments.
[0107] The analysis results are shown in FIG10 , which show that the fastest reaction is the cleavage of the target DNA guided by 5'P-gDNA, with a k obs The value was 0.04988 ± 0.003862, followed by the cleavage of the target RNA guided by 5'P-gDNA and 5'P-gRNA, with a k obs The values are 0.02071±0.002471 and 0.02451±0.003531, respectively.
[0108] Example 8 Effect of single-base mismatch between guide and target on the cleavage activity of PfAgo_K617G / L618G
[0109] In this case, the mutant PfAgo_K617G / L618G was used as an example to study the effect of single base mispairing at different sites on the enzyme cleavage activity of the mutant.
[0110] First, referring to the guide nucleic acid and target sequences described in Example 2, a series of gDNAs and gRNAs were designed and synthesized that differed from the original guide nucleic acid at different positions by a single base. These guide nucleic acids exhibited single-base mismatches with the target DNA or RNA. The sequences of guide nucleic acids with single-base mismatches at different positions are shown in Table 4.
[0111] Table 4
[0112] Then, these guide nucleic acids were 5'-terminally phosphorylated, and the target DNA and RNA were cleaved using 5'P-gDNA and the target RNA was cleaved using 5'P-gRNA as described in Example 2. The cleavage products were detected using 20% urea / polyacrylamide gel electrophoresis.
[0113] The test results are shown in Figure 11, which show that when the target DNA is cut under the guidance of 5'P-gDNA, single base mismatches at sites 2, 3, 4, 5, 7 in the seed region of the guide nucleic acid and sites 9, 11, and 12 in the central region will reduce the enzymatic activity of PfAgo_K617G / L618G, especially the single base mismatch at site 12 in the central region of the guide nucleic acid will significantly reduce its enzymatic activity. On the contrary, single base mismatches in the 5' anchor region, 3' supplementary region and 3' tail region of the guide nucleic acid do not significantly reduce its enzymatic activity. In fact, mismatches at some sites even increase the enzymatic activity. When the target RNA is cut under the guidance of 5'P-gDNA, single base mismatches at sites 8 in the seed region of the guide nucleic acid, sites 9, 11, and 12 in the central region, and sites 13 and 14 in the 3' supplementary region will reduce the enzymatic activity of PfAgo_K617G / L618G, especially the single base mismatch at site 3 Single-base mismatches at positions 13 and 14 in the 5' complement region abolished enzyme activity. In contrast, single-base mismatches in the 5' anchor region and 3' tail region of the guide nucleic acid did not significantly reduce its cleavage activity, and a single-base mismatch at position 10 in the central region of the guide nucleic acid actually enhanced the enzyme's cleavage activity. When cleaving target RNA under the guidance of 5' P-gRNA, single-base mismatches at positions 2, 3, 4, and 7 in the seed region of the guide nucleic acid, positions 9, 11, and 12 in the central region, and positions 13 and 14 in the 3' complement region reduced the enzyme's cleavage activity. In particular, single-base mismatches at positions 9 and 11 in the central region of the guide nucleic acid significantly reduced its cleavage activity. In contrast, single-base mismatches in the 5' anchor region and 3' tail region of the guide nucleic acid did not significantly reduce its cleavage activity, and a single-base mismatch at position 10 in the central region of the guide nucleic acid also enhanced the enzyme's cleavage activity.
[0114] Example 9 Detection of plasmid cleavage by PfAgo_K617G / L618G
[0115] In this case, the mutant PfAgo_K617G / L618G was used as an example to detect the mutant's plasmid DNA cleavage activity.
[0116] First, synthesize guide DNA targeting regions with varying GC content in the plasmid. Dilute the guide DNA to 100 μM in nuclease-free water, perform 5' phosphorylation on the guide DNA, and aliquot for future use. The sequences of the guide DNA targeting regions with varying GC content are shown in Table 5.
[0117] Table 5
[0118] 1 μM of a PfAgo mutant was premixed with 1 μM of either the forward or reverse guide nucleic acid in a reaction buffer containing 5 mM HEPES pH 7.5, 50 mM NaCl, 2 mM MnCl2, and 2.5% glycerol. The mixture was incubated at 60°C for 30 minutes to allow guide nucleic acid binding. The two reactions were then combined and 200 ng of the target plasmid pUC19 was added. The reaction was incubated at 37°C for 1 hour for target cleavage. Linear double-stranded DNA was then broken by digestion with NdeI or ScaI restriction enzymes in Cutsmart buffer at 37°C for 1 hour. The cleavage products were then mixed with 6× DNA loading buffer and analyzed by electrophoresis on a 1% agarose gel. The gel was stained with EB and visualized using a gel imaging system.
[0119] The detection results are shown in Figure 12, which show that as long as the PfAgo_K617G / L618G protein is added, the plasmid is mostly open circular (OC) and a small amount of linear (Lin) state; however, when a pair of 5'P-gDNA corresponding to the target region with 26% GC, 29% GC and 39% GC content is added, more linear products are detected compared to the addition of a single guide nucleic acid; then the above products are digested with restriction endonucleases (NdeI or ScaI), and product bands of the expected size are detected, indicating that PfAgo_K617G / L618G can specifically cut plasmid DNA at 37°C; when the GC content is 45% and 53%, no expected product bands are observed, indicating that the PfAgo_K617G / L618G plasmid cleavage efficiency is affected by the target GC content.
[0120] Example 10 Study on the Heat Resistance of PfAgo_K617G / L618G
[0121] In this example, to investigate the thermal stability of PfAgo_K617G / L618G, the enzyme was pre-bound to the guide nucleic acid at different temperatures, and then its cleavage activity at 37°C was tested (see Example 2 for the experimental process).
[0122] The results ( FIG13 ) showed that even when the incubation temperature was raised to 90° C., PfAgo_K617G / L618G still had good activity at 37° C.
[0123] Example 11 Effect of Temperature on PfAgo_K617G / L618G Cleavage Activity
[0124] This example investigates the effect of temperature on the cleavage activity of PfAgo_K617G / L618G. Specifically, the cleavage activity of 5'P-gDNA-guided tDNA, tRNA, and 5'P-gRNA-guided tRNA was tested at different temperatures. The guides, nucleic acids, and experimental procedures used in this experiment refer to those in Example 2.
[0125] The results ( FIG. 14 ) showed that the cleavage activity of PfAgo_K617G / L618G increased with increasing temperature in the range of 30°C-90°C.
[0126] Example 12 Comparison of cleavage rates of wild-type PfAgo and PfAgo_K617G / L618G at high temperatures
[0127] This example compares the cleavage rates of wild-type PfAgo and PfAgo_K617G / L618G at 95°C. Specifically, target DNA cleavage was performed over a time course at 95°C using 5'P-gDNA as a guide. The guide, nucleic acid, and experimental procedures used in this experiment refer to Example 2, and the cleavage rate analysis refers to Example 7.
[0128] The results ( FIG15 ) showed that the cleavage rate of PfAgo_K617G / L618G at 95° C. was also faster than that of wild-type PfAgo.
[0129] In summary, the PfAgo mutant proteins provided by the present invention not only have better cleavage activity at both moderate and high temperatures compared to wild-type PfAgo proteins, but also have a faster cleavage rate, effectively expanding the scope of use of PfAgo proteins. The present invention also provides nucleic acid expression vectors for preparing PfAgo mutant proteins, as well as compositions, kits, and methods for sequence-specific cleavage and editing of target nucleic acids, laying the foundation for the application of PfAgo mutant proteins in many fields of biotechnology, such as nucleic acid detection, molecular cloning, RNA, and genome editing.
[0130] The above descriptions are only some specific implementation methods of the present invention, and the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily conceived by any technician familiar with this technical field within the technical scope disclosed by the present invention should be covered by the protection scope of the present invention.
Claims
1. A PfAgo mutant protein having medium temperature target nucleic acid cleavage activity, characterized in that: The PfAgo mutant protein has an amino acid mutation at position 617 and / or position 618 relative to the sequence shown in SEQ ID NO.1, specifically: lysine at position 617 is mutated to other amino acids, and / or leucine at position 618 is mutated to other amino acids.
2. The PfAgo mutant protein according to claim 1, characterized in that The amino acid mutation of the PfAgo mutant protein is selected from: K617E / G; or L618Y / F / W / G.
3. A nucleic acid molecule encoding the PfAgo mutant protein according to claim 1 or 2.
4. An expression cassette, vector or transformant comprising the nucleic acid molecule of claim 3.
5. A nucleic acid cleavage system, characterized in that: The nucleic acid cleavage system comprises: Single-stranded guide nucleic acid; The PfAgo mutant protein according to claim 1.
6. The nucleic acid cleavage system according to claim 5, characterized in that The length of the single-stranded guide nucleic acid is 12 to 30 nt, and the single-stranded guide nucleic acid is 5'P-gRNA, 5'P-gDNA or 5'OH-gDNA.
7. Use of the nucleic acid cleavage system according to claim 5 in specifically cleaving target RNA or target DNA, characterized in that: A target RNA or a target DNA is added to the nucleic acid cleavage system, and the target RNA or the target DNA is complementary to the single-stranded guide nucleic acid sequence, and the PfAgo mutant protein specifically cleaves the target RNA or the target DNA under the guidance of the single-stranded guide nucleic acid; wherein the complementary pairing specifically refers to: The target RNA or target DNA has a nucleotide sequence that is completely complementary to the single-stranded guide nucleic acid sequence; Or the target RNA or target DNA has a nucleotide sequence that has a single, two, three, four or five base mismatches with the single-stranded guide nucleic acid sequence.
8. The use according to claim 7, characterized in that: The nucleic acid cleavage system contains Mn 2+ Mg 2+ and / or Co 2+ .
9. Use of the PfAgo mutant protein according to claim 1 or the nucleic acid cleavage system according to claim 5 in gene editing.
10. Use of the PfAgo mutant protein according to claim 1 in preparing a nucleic acid detection kit.
Citation Information
Patent Citations
Novel thermophilic endonuclease mutant as well as preparation method and application thereof
CN114561374A
High-temperature Argonaute protein and application thereof
CN115820604A
Application of medium-high temperature Argonaute protein in specific cleavage of target nucleic acid
CN115975985A
Nucleic acid detection method based on medium-temperature Argonaute protein and isothermal amplification
CN116064736A
Programmable DNA-Guided Artifical Restriction Enzymes
US20210087604A1
Cited By
TtdAgo mutant protein with normal-temperature target nucleic acid cleavage activity and application of TtdAgo mutant protein
CN119752848A
PfAgo-based geminivirus dual detection test strip as well as preparation method and application thereof
CN119757736A
